Header

UZH-Logo

Maintenance Infos

Positronen-Emissions-Tomographie in der Demenzdiagnostik


Gietl, Anton F (2015). Positronen-Emissions-Tomographie in der Demenzdiagnostik. Schweizer Archiv für Neurologie und Psychiatrie, 166(4):126-134.

Abstract

The use of positron emission tomography (PET) for diagnosing dementia especially relies upon the PET tracer uorodeoxyglucose (FDG-PET) and various tracers for detecting the presence of beta-amyloid deposits (amyloid-PET). Reduced cerebral glucose metabolism caused by nerve damages is assessed using FDG-PET. Different neurodegenerative dis- orders can be distinguished through the varying damage patterns they exhibit.
If the amyloid-PET fails to detect the presence of plaques, the Alzheimer’s diagnosis is highly unlikely. Patients displaying normal cognitive behav- iour may, however, frequently exhibit abnormal amyloid-PET results with increasing age.
FDG-PET and amyloid-PET are incorporated as relevant biomarkers into the diagnostic criteria for neurodegenerative diseases. These tools thus help to increase diagnostic reliability and to detect early stages. Research- ers deem this necessary, as neurodegenerative diseases may remain asymptomatic for decades and the initial appearance of symptoms is already preceded by considerable loss of synapses and neurons. Drug treatment is presently thought to be effective particularly during early stages. Amyloid-PET is well-suited for the early diagnosis of asympto- matic Alzheimer’s pathologies and its results serve as a selection criterion in clinical trials.

Abstract

The use of positron emission tomography (PET) for diagnosing dementia especially relies upon the PET tracer uorodeoxyglucose (FDG-PET) and various tracers for detecting the presence of beta-amyloid deposits (amyloid-PET). Reduced cerebral glucose metabolism caused by nerve damages is assessed using FDG-PET. Different neurodegenerative dis- orders can be distinguished through the varying damage patterns they exhibit.
If the amyloid-PET fails to detect the presence of plaques, the Alzheimer’s diagnosis is highly unlikely. Patients displaying normal cognitive behav- iour may, however, frequently exhibit abnormal amyloid-PET results with increasing age.
FDG-PET and amyloid-PET are incorporated as relevant biomarkers into the diagnostic criteria for neurodegenerative diseases. These tools thus help to increase diagnostic reliability and to detect early stages. Research- ers deem this necessary, as neurodegenerative diseases may remain asymptomatic for decades and the initial appearance of symptoms is already preceded by considerable loss of synapses and neurons. Drug treatment is presently thought to be effective particularly during early stages. Amyloid-PET is well-suited for the early diagnosis of asympto- matic Alzheimer’s pathologies and its results serve as a selection criterion in clinical trials.

Statistics

Downloads

48 downloads since deposited on 29 Dec 2015
33 downloads since 12 months
Detailed statistics

Additional indexing

Other titles:Die molekulare Ebene neurodegenerativer Erkrankungen sichtbar machen
Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > Institute for Regenerative Medicine (IREM)
Dewey Decimal Classification:610 Medicine & health
Language:German
Date:2015
Deposited On:29 Dec 2015 09:40
Last Modified:14 Feb 2018 10:18
Publisher:EMH Swiss Medical Publishers
ISSN:0258-7661
OA Status:Gold
Free access at:Publisher DOI. An embargo period may apply.
Official URL:http://sanp.ch/

Download

Download PDF  'Positronen-Emissions-Tomographie in der Demenzdiagnostik'.
Preview
Content: Published Version
Filetype: PDF
Size: 274kB
Licence: Creative Commons: Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)